Shannon Jackson
Psychiatric/Mental Health · Shreveport, LANPI 1811323645
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.8% of the total across 375 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 32.0% of the total. 2025 is the largest year on record at $2,524, more than ten times the $191 reported in 2021. Among psychiatric/mental health clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 375 payments — averaging $20.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$2K
- Neurocrine Biosciences, Inc.$1K
- Alkermes, Inc.$1K
- AbbVie$716
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$590
- Johnson & Johnson$545
- plus $1K from 9 others
What the payments were for
- Food & beverage$7,36396%
- Education$3274%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 81 | $2,460 |
| Neurocrine Biosciences, Inc. | 60 | $1,067 |
| Alkermes, Inc. | 60 | $1,005 |
| AbbVie | 62 | $716 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 24 | $590 |
| Johnson & Johnson | 29 | $545 |
| E.r. Squibb & Sons, L.L.C. | 21 | $447 |
| Otsuka America Pharmaceutical, Inc. | 16 | $326 |
| Vanda Pharmaceuticals Inc. | 5 | $193 |
| Indivior Inc. | 9 | $132 |
| Amgen(2 entities) | 4 | $82 |
| Boston Scientific | 1 | $71 |
| AstraZeneca | 1 | $24 |
| Cumberland Pharmaceuticals, Inc. | 1 | $19 |
| Sanofi | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$1,479
- ARISTADA$944
- Austedo XR$750
- VRAYLAR$369
- INGREZZA$265
- COBENFY$260
- AUSTEDO$250
- CAPLYTA$250
- UZEDY$247
- ARISTADA INITIO$236
- ABILIFY MAINTENA$125
- INVEGA SUSTENNA$125
- Fanapt$125
How this compares
$7,689 in reported general payments places this provider in the 90th percentile of 615 psychiatric/mental health providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega TrinzaPaliperidone Palmitate | 21 | $229,819 |
| Invega SustennaPaliperidone Palmitate | 27 | $93,159 |
| AristadaAripiprazole Lauroxil | 13 | $41,548 |
| Abilify MaintenaAripiprazole | 13 | $37,743 |
| VraylarCariprazine Hcl | 14 | $21,008 |
| Paliperidone ErPaliperidone | 12 | $2,430 |
| Benztropine Mesylate | 101 | $1,708 |
| Haloperidol Decanoate | 38 | $1,262 |
| Sertraline Hcl | 54 | $945 |
| Haloperidol | 25 | $895 |
| Quetiapine Fumarate | 50 | $856 |
| Oxcarbazepine | 26 | $808 |
| Hydroxyzine Pamoate | 58 | $745 |
| AmantadineAmantadine Hcl | 12 | $613 |
| Trazodone Hcl | 37 | $455 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Trinza, Invega Sustenna | $545 | $322,97848 claims |
| Alkermes, Inc.Aristada | $1,005 | $41,54813 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $326 | $37,74313 claims |
| AbbVieVraylar | $716 | $21,00814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 615 psychiatric/mental health providers in Louisiana.
Other psychiatric/mental health in Shreveport
- Kimberly ForcinelShreveport$92K
- Zachary FussellShreveport$9K
- Lisa BakerShreveport$9K
- Jaschandria BellShreveport$8K
- Amy LacoutureBaton Rouge$663K
- Amanda EymardHouma$617K
- Amber LittlefieldBroussard$225K
- Timothy PellegrinHouma$210K
- Melissa GuilbeauLafayette$122K
- Sattaria DilksLake Charles$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.